Essential thrombocythemias without V617F JAK2 mutation are clonal hematopoietic stem cell disorders.
Kiladjian
J-J
JJ
Elkassar
N
N
Cassinat
B
B
Hetet
G
G
Giraudier
S
S
Balitrand
N
N
Conejero
C
C
Briere
J
J
Fenaux
P
P
Chomienne
C
C
Grandchamp
B
B
D000293:Adolescent; D000328:Adult; D000368:Aged; D002999:Clone Cells / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006412:Hematopoietic Stem Cells / Q000473:pathology*; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D016898:Interferon-alpha / Q000627:therapeutic use; D053614:Janus Kinase 2; D008875:Middle Aged; D009154:Mutation; D011505:Protein-Tyrosine Kinases / Q000235:genetics*; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D013920:Thrombocythemia, Essential / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology*; D016896:Treatment Outcome
D016898:Interferon-alpha; D011518:Proto-Oncogene Proteins; D011505:Protein-Tyrosine Kinases; C507924:JAK2 protein, human; D053614:Janus Kinase 2; D006918:Hydroxyurea